Nearly half of patients prescribed GLP-1 receptor agonists discontinue therapy within the first year, according to a 2025 JAMA cohort study of 125,474 patients: 46.5% of patients with type 2 diabetes and 64.8% of patients without diabetes stopped treatment within one year of starting. A 2026 Lancet eClinical Medicine systematic review confirmed that weight regain after cessation is rapid and substantial, with patients retaining only about 40% of their on-treatment weight loss at one year post-cessation. The reasons for discontinuation range from gastrointestinal side effects and supply shortages to insurance gaps, surgical procedures, and cost. When patients are ready to restart, the clinical path is straightforward in principle — re-titrate from a lower dose to minimize adverse events — but the payer and documentation workflow is anything but.
This article is for market access teams, manufacturer hub operators, specialty pharmacy coordinators, provider-office access staff, and reimbursement specialists who need to understand how GLP-1 treatment interruptions interact with prior authorization requirements, what documentation payers demand for restart, and how to prevent a gap from becoming a permanent coverage loss.
Why patients interrupt GLP-1 therapy
Treatment interruptions for GLP-1 drugs fall into four broad categories, each with different payer implications:
| Interruption reason | Typical gap duration | Payer significance |
|---|---|---|
| Gastrointestinal side effects (nausea, vomiting, diarrhea) | 2–8 weeks | May require documentation of tolerance attempt before restart |
| Drug shortage or supply disruption | 4–12+ weeks | Shortage history may support automatic reauthorization; varies by plan |
| Surgery, endoscopy, or medical procedure | 2–6 weeks | Planned interruption; documentation straightforward |
| Insurance lapse, prior authorization denial, cost | 4–52+ weeks | Highest risk of coverage loss; may require new PA from scratch |
A JAMA Network Open study published in August 2025 examined Medicare Part D coverage and prior authorization policies for semaglutide and tirzepatide. The study documented that PA requirements for GLP-1 drugs have tightened through 2025–2026, with more plans requiring documented BMI thresholds, comorbidity criteria, prior failed weight-loss attempts, and ongoing lifestyle-modification documentation.
Clinical restart protocols: what the labeling does and does not say
The FDA-approved prescribing information for Wegovy (semaglutide), Zepbound (tirzepatide), Ozempic (semaglutide), and Mounjaro (tirzepatide) does not provide specific guidance for treatment resumption after interruptions. This absence of labeled instructions creates variability in clinical practice and payer expectations.
Semaglutide (Wegovy, Ozempic) restart
Semaglutide has a half-life of approximately one week. After four to five weeks without a dose, the drug is substantially eliminated from the body. Clinical practice generally supports restarting at the lowest dose (0.25 mg for Wegovy; 0.25 mg for Ozempic) and re-titrating through the standard escalation schedule:
| Week | Wegovy dose | Ozempic dose |
|---|---|---|
| 1–4 | 0.25 mg weekly | 0.25 mg weekly |
| 5–8 | 0.5 mg weekly | 0.5 mg weekly |
| 9–12 | 1.0 mg weekly | 1.0 mg weekly |
| 13–16 | 1.7 mg weekly | 2.0 mg weekly |
| 17+ | 2.4 mg weekly | — |
The key clinical rationale is minimizing gastrointestinal side effects upon reintroduction. A patient who tolerated 2.4 mg before the interruption may experience significant nausea, vomiting, or diarrhea if restarted at the same dose after a multi-week gap, because GLP-1 receptor sensitivity resets during the drug-free period.
Tirzepatide (Zepbound, Mounjaro) restart
Tirzepatide has a half-life of approximately five days. After two to three weeks without a dose, the drug is substantially eliminated. Clinical guidance from prescribers and weight-management programs typically recommends restarting tirzepatide at 2.5 mg weekly regardless of the dose at the time of interruption, then re-titrating:
| Week | Zepbound/Mounjaro dose |
|---|---|
| 1–4 | 2.5 mg weekly |
| 5–8 | 5 mg weekly |
| 9–12 | 7.5 mg weekly |
| 13–16 | 10 mg weekly |
| 17–20 | 12.5 mg weekly |
| 21+ | 15 mg weekly |
As with semaglutide, the restart dose is conservative because gastrointestinal tolerance cannot be assumed after a gap.
Weight regain during interruption: what happens and why it matters
The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, documented that patients who stopped semaglutide regained approximately two-thirds of their lost weight within one year. A 2026 Lancet eClinical Medicine systematic analysis confirmed that weight regain after GLP-1 cessation is both rapid and substantial, with most regain occurring in the first three months after discontinuation.
For payers, weight regain during an interruption creates a specific documentation problem. A patient who started GLP-1 therapy at a BMI of 35 and dropped to BMI 28 before interrupting may have regained enough weight to exceed the original threshold — or may not. Payers that anchor eligibility to current BMI rather than BMI at therapy initiation may deny reauthorization if the patient's BMI has risen above the plan's cutoff but falls below the original starting BMI.
The ICER Final Evidence Report on semaglutide and tirzepatide for obesity, published in December 2025, recommended that payers "use a patient's starting weight, not current weight, as the basis for judging whether further treatment is necessary" because "clinical trial data demonstrate a high likelihood of weight regain after discontinuation in most patients."
Prior authorization and reauthorization after an interruption
New PA vs. continuation
Whether a treatment interruption triggers a new prior authorization or a continuation request depends on the payer, the plan, and the gap duration. Three scenarios are common:
Short gap (under 30 days): Most plans treat this as a continuation. The existing PA remains active, and the pharmacy can dispense at the restart dose. Some plans may not require any notification.
Medium gap (30–90 days): Many plans require a continuation or reauthorization request. The prescriber must document the reason for the interruption and affirm that the patient continues to meet coverage criteria.
Long gap (over 90 days): Most plans treat this as a new PA. The prescriber must submit a complete authorization package: current BMI, diagnosis codes, comorbidity documentation, step therapy history, and lifestyle-modification attestation.
What payers want in the restart PA
Payer requirements for GLP-1 restart authorization vary, but the following documentation elements are commonly required:
| Documentation element | Why payers request it | How to prepare |
|---|---|---|
| Current BMI | Confirm continued eligibility under plan thresholds | Obtain a measured weight within 30 days of restart request |
| BMI at original therapy initiation | For plans that use starting BMI (per ICER recommendation) | Reference original PA approval or clinical notes from initiation visit |
| Reason for interruption | Side effect, shortage, surgery, insurance gap | Include clinical notes documenting the interruption |
| Duration of interruption | Determines whether new PA or continuation | Document start and end dates of gap |
| Restart dose and titration plan | Confirm clinical appropriateness of re-titration | Reference prescriber's titration schedule |
| Continued lifestyle modification | Ongoing plan requirement | Attestation or documentation of diet/exercise program |
| Adherence to prior therapy before interruption | Demonstrates good-faith treatment attempt | Pharmacy fill records, prescriber notes |
Highmark's Medical Assistance Handbook for GLP-1 receptor agonists, updated March 2, 2026, defines therapeutic failure as "failure to achieve positive clinical outcome(s) while utilizing the maximum FDA-approved dose of the GLP-1 receptor agonist with documentation of adherence." This language suggests that patients who interrupted before reaching the maximum dose may face additional scrutiny on restart, because they may not meet the plan's definition of having completed an adequate trial.
Step therapy implications on restart
Some plans may treat a treatment gap as a reset of the step therapy sequence. A patient who completed step therapy for Wegovy, interrupted, and now wants to restart Wegovy should not need to repeat the step therapy sequence — but a patient who wants to switch from Wegovy to Zepbound after a gap may be required to complete a new step therapy sequence, depending on the plan's criteria.
Pennsylvania's Medical Assistance Bulletin on GLP-1 prior authorization, effective January 1, 2026, specifies that for Zepbound, the patient must demonstrate "a history of therapeutic failure of or a contraindication or an intolerance to the maximum FDA-approved doses of Ozempic, Wegovy, and Mounjaro that would not be expected to occur with the requested drug." This type of sequencing requirement does not automatically reset after a gap, but the burden of documentation falls on the prescriber.
Coverage friction after shortage-driven interruptions
The FDA removed tirzepatide from the drug shortage list in December 2024 (initially removed October 2, 2024, then remanded by court and re-confirmed December 19, 2024) and semaglutide in February 2025. For patients who interrupted GLP-1 therapy during the shortage period (2022–2024), the restart path may intersect with the transition from compounded to branded product.
Payers do not recognize compounded semaglutide or tirzepatide as step therapy or prior therapy for purposes of PA criteria. A patient who used compounded semaglutide during the Wegovy shortage, then stopped when the shortage resolved, and now wants to restart on branded Wegovy will need to start the PA process from scratch. The compounded use does not count as a trial of the branded product.
CVS Caremark removed Zepbound from its standard commercial formulary effective July 1, 2025, making Wegovy the preferred GLP-1. However, on May 28, 2026, CVS Caremark announced it would add Zepbound back to commercial formularies as an additional preferred option effective October 1, 2026, alongside Wegovy. Patients restarting Zepbound between July 2025 and October 2026 may face formulary restrictions, but those restarting after October 2026 should find both Zepbound and Wegovy available as preferred options.
How hub and access teams should manage the restart workflow
Before the interruption (prospective documentation)
- Record the patient's BMI at therapy initiation
- Document the dose at which the patient was stable
- Capture the reason for any planned interruption
- Confirm PA expiration date and whether the plan allows continuation after a gap
During the interruption
- Track the gap duration against the plan's PA expiration window
- If the gap approaches 90 days, alert the prescriber that a new PA may be needed
- For shortage-driven gaps, maintain records of the FDA shortage status and the specific product and dose that was unavailable
At restart
- Obtain a current weight and BMI
- Confirm the restart dose (typically lowest dose per clinical practice)
- Submit PA documentation that includes:
- Original start date, dose, and BMI at initiation
- Reason for interruption with clinical documentation
- Restart dose and planned titration schedule
- Continued lifestyle modification attestation
- If switching products after a gap, check formulary status before submitting the PA
Common failure points
Prescriber restarts at the pre-gap dose without re-titration: Payer may not object, but the patient is at higher risk of gastrointestinal adverse events and may abandon therapy.
PA expires during the gap and nobody notices: Pharmacy attempts to fill, claim rejects for PA required, and the patient is stranded without medication while the new PA is processed.
BMI at restart exceeds plan threshold but is below original BMI: Some plans will deny; others will accept starting BMI. Know the specific plan's policy before submitting.
Switch from diabetes-branded to obesity-branded product after a gap: A patient who was on Ozempic for diabetes, interrupted, and now wants Wegovy for obesity faces a different PA pathway. The diabetes PA does not carry over to the obesity indication.
Compounded product use during gap not recognized: Payers do not count compounded GLP-1 use toward step therapy or therapeutic trial requirements.
What to monitor next
CMS guidance on GLP-1 Bridge restarts: The Medicare GLP-1 Bridge demonstration launches July 1, 2026. CMS has not yet published specific restart documentation requirements for Bridge participants who interrupt therapy. Expect guidance before the launch date.
Plan-specific reauthorization policies post-shortage: As the shortage era recedes, some plans may tighten reauthorization criteria for patients who previously received GLP-1 therapy but interrupted for more than 90 days.
Weight-regain documentation as medical necessity evidence: As evidence accumulates on the near-universality of weight regain after GLP-1 cessation, payers may adopt policies that favor continuation authorization based on regain risk rather than requiring current BMI to exceed a threshold.
Oral GLP-1 restart pathways: Oral semaglutide (Wegovy tablets) and orforglipron (Foundayo) introduce oral restart protocols that may differ from injectable re-titration, particularly around gastrointestinal tolerability and dose escalation speed.
This article provides general information about GLP-1 treatment interruption and payer documentation requirements. It does not constitute medical advice, reimbursement guidance for any specific patient or plan, or legal guidance on compounding regulations. Coverage policies vary by plan, state, and product. Always verify current payer criteria before submitting prior authorization requests.
Sources
- JAMA. "Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity." Published 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11786232
- Lancet eClinical Medicine. "Trajectory of weight regain after cessation of GLP-1 receptor agonists." Published March 4, 2026. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00043-X/fulltext
- JAMA Network Open. "Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans." Published August 29, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12397888
- Institute for Clinical and Economic Review (ICER). "Semaglutide and Tirzepatide for Obesity: Final Policy Recommendations." Published December 16, 2025. https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Policy-Recommendations_For-Publication_121625.pdf
- Highmark Medical Assistance Handbook. "Prior Authorization of GLP-1 Receptor Agonists." Updated March 2, 2026. https://providers.highmark.com/content/dam/highmark/en/providerresourcecenter/wholecare/documents/pdfs/resource-centers/medical-assistance-bulletins/mab-prior-auth-GLP-1-receptor-agonists.pdf
- Pennsylvania Department of Human Services. "Medical Assistance Bulletin: Coverage Change and Prior Authorization of GLP-1 Receptor Agonists." Effective January 1, 2026. https://www.pa.gov/content/dam/copapwp-pagov/en/dhs/documents/docs/publications/documents/forms-and-pubs-omap/mab2025112403.pdf
- Fella Health. "Restarting Tirzepatide After a Month: Safe Resumption Guide." 2026. https://www.fellahealth.com/guide/restarting-tirzepatide-after-a-month
- Prime Therapeutics. "GLP-1 Pipeline Update: May 2026." https://www.primetherapeutics.com/glp-1-pipeline-update-may-2026
- ZS. "Medicare Part D Reform: Pharma's Impact and Opportunities in IRA." https://www.zs.com/insights/ira-medicare-part-d-changes-mppp-how-pharma-can-prepare
- Managed Healthcare Executive. "CVS Caremark to put Zepbound back on formulary and add Foundayo." May 28, 2026. https://www.managedhealthcareexecutive.com/view/cvs-caremark-to-put-zepbound-back-on-formulary-and-add-foundayo
- FDA. "Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products." December 19, 2024. https://www.fda.gov/media/184606/download
- FDA. "Semaglutide Removed from FDA 506e Shortage List." February 21, 2025. https://www.frierlevitt.com/articles/semaglutide-removed-fda-506e-shortage-list
